4 March 2024
Kromek Group
plc
("Kromek"
or the "Group")
Result of
General Meeting
Kromek Group plc, a leading developer of
radiation and bio-detection technology solutions for the advanced
imaging and CBRN detection segments, announces that at a General
Meeting held earlier today, all resolutions were duly
passed.
Details of the proxy voting results, which
should be read alongside the Notice of General Meeting, are
below:
|
Resolution
|
Votes for
|
Votes
against
|
Votes
withheld
|
Total proxy
votes
|
|
|
No. of
votes
|
% of votes
cast*
|
No. of
votes
|
% of votes
cast*
|
No. of
votes
|
|
|
1
|
208,359,813
|
99.30
|
1,468,177
|
0.70
|
865,908
|
210,693,898
|
|
2
|
207,152,990
|
98.62
|
2,895,210
|
1.38
|
645,698
|
210,693,898
|
*Excludes withheld votes
For
further information, please contact:
|
Kromek Group
plc
|
|
|
Arnab Basu, CEO
Paul Farquhar,
CFO
|
+44 (0)1740 626 060
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
|
Geoff Nash/Giles Balleny/Seamus
Fricker - Corporate Finance
Tim Redfern - ECM
|
+44 (0)20
7220 0500
|
|
Michael Johnson/Tamar Cranford-Smith - Sales
|
|
|
Gracechurch Group
(Financial PR)
|
|
|
Harry Chathli/Claire Norbury/Henry Gamble
|
+44 (0)20 4582 3500
|
Kromek Group
plc
Kromek Group plc is a leading developer of radiation
detection and bio-detection technology solutions for the advanced
imaging and CBRN detection segments. Headquartered in County
Durham, UK, Kromek has manufacturing operations in the UK and US,
delivering on the vision of enhancing the quality of life through
innovative detection technology
solutions.
The advanced imaging segment comprises the medical
(including CT and SPECT), security and industrial markets. Kromek
provides its OEM customers with detector components, based on its
core cadmium zinc telluride (CZT) platform, to enable better
detection of diseases such as cancer and Alzheimer's, contamination
in industrial manufacture and explosives in aviation
settings.
In CBRN detection, the Group provides nuclear
radiation detection solutions to the global homeland defence and
security market. Kromek's compact, handheld, high-performance
radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect
critical infrastructure, events, personnel and urban environments
from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions
in the CBRN detection segment. These consist of fully automated and
autonomous systems to detect a wide range of airborne
pathogens.
Kromek is listed on AIM, a market of the London Stock
Exchange, under the trading symbol
'KMK'.